“We are very excited about the CE certification of our MSOT Acuity Echo system. The integration of ultrasound imaging is key for clinical users of optoacoustics” said Christian Wiest, CEO and co-founder of iThera Medical. Dr Philipp Bell, Chief Commercial Officer at iThera and Coordinator of EUPHORIA said “Obtaining the CE mark is a major milestone for the EUPHORIA project. We see huge potential for the MSOT Acuity Echo and the opportunity for non-invasive patient imaging that it presents”.
MSOT (multispectral optoacoustic tomography), based on the photoacoustic effect (the emission of acoustic signals following light absorption) has the unique capability to visualize optical contrast at high resolution, in deep tissue in real-time. By tuning the wavelength of the excitation laser, it can discriminate tissue chromophores that have a characteristic spectrum in the near-infrared; particularly haemoglobin, lipids, collagen, and water. The combination of optoacoustic imaging with ultrasound allows the clinician to identify relevant anatomical structures based on the ultrasound image and then probe the tissue of interest for functional and molecular biomarkers using MSOT.
The technology behind iThera’s MSOT Acuity Echo was optimized as part of the EUPHORIA Project. We aim to test the efficacy of the new system as a clinical tool for non-invasive monitoring of Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis. A multi-site clinical study in people with IBD is currently underway in four hospitals in Germany and Italy.